Publication:
Serum leptin levels, skin leptin and leptin receptor expression in psoriasis

Simple item page
dc.contributor.authorERGUN, SAFİYE ATLAS TÜLİN
dc.contributor.authorsCerman, A. A.; Bozkurt, S.; Sav, A.; Tulunay, A.; Elbasi, M. O.; Ergun, T.
dc.date.accessioned2022-03-12T17:33:53Z
dc.date.available2022-03-12T17:33:53Z
dc.date.issued2008
dc.description.abstractBackground Recent studies support the relation of psoriasis with obesity and cardiovascular disease. Leptin, a peptide hormone secreted predominantly from adipose tissue, is involved in the regulation of energy intake and expenditure. Recently, it has been shown to have several immunological effects including induction of proinflammatory cytokine production. Objectives To investigate the possible role of leptin in psoriasis pathogenesis. Methods Forty-three patients with psoriasis, 10 diseased and 10 healthy controls with normal body mass index were included. Serum fasting leptin levels of the study group were examined by enzyme-linked immunosorbent assay. Tissue leptin and leptin receptor expression of both patients and controls were investigated by immunohistochemistry. Results Serum leptin levels, tissue leptin and leptin receptor expression were significantly higher in patients with severe psoriasis than patients with mild-moderate psoriasis and controls (P < 0.05). Serum leptin levels showed a positive correlation with Psoriasis Area and Severity Index and involved body surface area in patients with psoriasis. In addition, serum leptin levels, tissue leptin and leptin receptor expression showed a positive correlation with disease duration in patients with psoriasis (P < 0.01, r = 0.979; P < 0.01, r = 0.691; P < 0.01, r = 0.428, respectively). Conclusions We assume that leptin might serve as a marker of severity in psoriasis and also may be a pathogenetic cofactor contributing to chronicity of the disease. Consequently, its role in obesity and cardiovascular disease in patients with psoriasis deserves to be studied. In addition, drugs targeting the proinflammatory effects of leptin may be a new adjuvant therapeutic approach in psoriasis.
dc.identifier.doi10.1111/j.1365-2133.2008.08742.x
dc.identifier.eissn1365-2133
dc.identifier.issn0007-0963
dc.identifier.pubmed18637894
dc.identifier.urihttps://hdl.handle.net/11424/228930
dc.identifier.wosWOS:000259307700006
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofBRITISH JOURNAL OF DERMATOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectleptin
dc.subjectleptin receptor
dc.subjectpsoriasis
dc.subjectPsoriasis Area and Severity Index
dc.subjectIMMUNE-RESPONSE
dc.subjectRISK
dc.subjectINFLAMMATION
dc.subjectSMOKING
dc.subjectOBESITY
dc.subjectDISEASE
dc.titleSerum leptin levels, skin leptin and leptin receptor expression in psoriasis
dc.typearticle
dspace.entity.typePublication
local.avesis.id23ae6fe5-1a10-4977-ad29-2053ea9ba71f
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages7
oaire.citation.endPage826
oaire.citation.issue4
oaire.citation.startPage820
oaire.citation.titleBRITISH JOURNAL OF DERMATOLOGY
oaire.citation.volume159
relation.isAuthorOfPublication63703755-08da-47f9-b27c-f7c8c0426f83
relation.isAuthorOfPublication.latestForDiscovery63703755-08da-47f9-b27c-f7c8c0426f83

Files

Collections

Research Outputs